BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Bio Essence Corp. BIOE
6 fiscal years on record · USD · FY2025 reported · SEC filings only
$896,197
In brief
What this company does
Written from the business description in Bio Essence Corp.'s annual report to the U.S. Securities and Exchange Commission, filed 27 March 2026. Every sentence was checked against that document before publication.
Growth
USD 1.9M
Revenue, FY2025 · full 6-year series below
Revenue $M
Net income $M
FY2025 · Revenue 1.9 · Net income 0.9
Compound annual growth
Revenue compounded at +14.6% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
47 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 47.4% · Net 47.2%
ROE
Not applicable: equity was negative in this period, so return on equity has no meaning.
The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | · | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | · | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | · | −0.03 | −0.03 | −0.02 | −0.02 | −0.02 |
| Dividend / sh $ | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · |
| ROE % | · | · | · | · | · | · |
| Shares out B | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 30 reconciliationsAUDITED
Reconciled in 7 of 19 fiscal years. 65 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inCalifornia
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2019